Elucidating the mechanism of

This team will determine the mechanisms by which CBP/p300 drives prostate cancer progression and identify biomarkers that can be used to select patients most likely to benefit from treatment with CBP/p300-inhibitors.

2017 PCF Challenge Award (

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.

2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

||

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 PCF Challenge Award (

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.

2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

||

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award (

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.

2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

||

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.

2017 PCF Challenge Award (

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.

This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.

2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

||

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles) Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles) Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Merkin, Todd Boehly Principal Investigators: Isla Garraway, MD, Ph D (University of California, Los Angeles), Beatrice Knudsen, MD, Ph D (Cedars-Sinai Medical Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, Ph D (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, Ph D (Cold Spring Harbor Laboratory), Sungyong You, Ph D (Cedars-Sinai Medical Center), Arkadiusz Gertych, Ph D (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles) Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population Description: What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment.This team will develop tests to measure cognitive impairment and identify men at risk, and test an intervention to prevent cognitive decline in prostate cancer patients being treated with androgen-targeted therapy.2017 PCF Challenge Award ($1 Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

Million) Award Donors: Steve Roth, Janssen Pharmaceuticals Principal Investigators: Karen Knudsen, Ph D (Thomas Jefferson University), Johann de Bono, MD, Ph D (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Myles Brown, MD (Harvard: Dana Farber Cancer Institute) Co-Investigators: Matthew Schiewer, Ph D (Thomas Jefferson University), Adam Sharp, Ph D, MSc (The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust), Gunther Boysen, Ph D (The Institute of Cancer Research and Royal Marsden Hospital), Henry Long, Ph D (Harvard: Dana Farber Cancer Institute), Laura Cato, Ph D (Harvard: Dana Farber Cancer Institute) Project Title: Targeting CBP/p300 to Suppress Oncogenic Transcription Factors in Advanced Prostate Cancer Description: What this means to patients: New treatments are urgently needed for men with advanced prostate cancer to prevent death from this disease.

Search for elucidating the mechanism of:

elucidating the mechanism of-15elucidating the mechanism of-41elucidating the mechanism of-22elucidating the mechanism of-9

Leave a Reply

Your email address will not be published. Required fields are marked *

One thought on “elucidating the mechanism of”

  1. knows that the chemistry between Asher Dov Angel and Peyton Elizabeth Lee (er, Jonah Beck and Andi Mack) is so real. The cutie also let us in on where Jonah and Andi's relationship goes in the second season. I don't know if they're gonna be friends or more than friends." We have hope that Andi and Jonah will end up together in Season 2, but we suppose we'll just have to wait and see. Just one glance at their Instagram pages, and you'll see they really are inseparable IRL too. And it was a lot of fun," she spilled in an interview. I love his voice so much." "Dodgers game with this one💙😉," Madisyn captioned a selfie of her and Asher at a baseball game together, winky face and all.